CD274 and melanoma: PD-L1 predicted the clinical outcome of only 28.9% of cancer patients treated with ICBs [36] and showed no correlation to treatment outcome determination in patients with melanoma, Merkel cell carcinoma, RCC, or hepatocellular carcinoma [6,36].